CLOSEOUT LETTER
Eurotrol B. V.
- Recipient:
- Eurotrol B. V.
United States
- Issuing Office:
United States
| |
10903 New Harrpshire Avenue Silver Spring, MD 20993 |
MAR 17, 2017
Mr. Daniel Philippens
QA/RA Director
Eurotrol B.V.
Keplerlaan 20
Ede Gld, Gelderland
6716 BS Netherlands
Dear Mr. Philippens:
The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter [CMS#433999] dated November 19, 2014. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely yours,
/S/
Donald J. St. Pierre
Acting Deputy Director for
Patient Safety and Product Quality
Office of ln Vitro Diagnostics and Radiological Health
Center for Devices and Radiological Health